Literature DB >> 35047758

BAG3-related myofibrillar myopathy: a further observation with cardiomyopathy at onset in pediatric age.

Gaia Scarpini1, Maria Lucia Valentino2,3, Melania Giannotta1, Luca Ragni4, Annalaura Torella5, Marta Columbaro6, Vincenzo Nigro5, Antonella Pini1.   

Abstract

Myofibrillar myopathies are a heterogeneous group of neuromuscular disorders characterized by degeneration of Z-disk, causing the disintegration of myofibrils. They may be caused by mutations in different genes, among these, the BAG3 gene (Bcl-2 associed-athanogene-3) encodes a multidomain protein that plays an important role in many cellular processes. We report the case of a 16-year-old male who at 4 years of age presented with a hypertrophic obstructive cardiomyopathy, then developed axonal sensory motor polyneuropathy, muscle weakness, rigid spine, severe kyphoscoliosis and respiratory failure. Muscle biopsy showed the typical hallmark of myofibrillar myopathy with abnormal cytoplasmic expression of multiple proteins. Ade novo heterozygous common mutation in the BAG3 gene with a c.626C > T (p.Pro209Leu) was discovered on NGS genetic analysis. Mutations in the BAG3 gene are causes of a severe and progressive condition and natural history data are important to be collected. An early diagnosis is critical for prognostic implications in cardiomyopathy and respiratory failure treatment. ©2021 Gaetano Conte Academy - Mediterranean Society of Myology, Naples, Italy.

Entities:  

Keywords:  BAG3; cardiomyopathy; myofibrillar myopathy; pediatric neuromuscular disorder

Mesh:

Substances:

Year:  2021        PMID: 35047758      PMCID: PMC8744013          DOI: 10.36185/2532-1900-061

Source DB:  PubMed          Journal:  Acta Myol        ISSN: 1128-2460


Introduction

Myofibrillar myopathies (MFM) are a heterogeneous group of neuromuscular disorders caused by mutations of different genes that share myopathological features, first of all the disintegration of Z-disks followed by myofibrillar disruption and ectopic accumulation of multiple proteins [1]. Each gene produces a mutated protein which is an integral part of the Z-disk or is closely associated with it. The clinical manifestations of various subtypes can change and may include different age of onset (from childhood to late adulthood) and distal more than proximal weakness, cardiopathy, respiratory failure, cataracts or peripheral neuropathy in various combinations. The diagnosis of MFM is based on clinical findings, electromyography, nerve conduction studies and muscle histology. The most frequent inheritance pattern of the MFM-causing genes is autosomal dominant, and in a significant number of patients the mutation occurs de novo [2-3]. An early-onset subtype of MFM is caused by a mutation in BAG3 gene on chromosome 10, encoding for the antiapoptotic Bag3 (Bcl-2 associed-athanogene-3) protein. Bag3 is a multi-domain protein that regulates the Hsp70 family of molecular chaperones and that interacts with many other polypeptides, strongly expressed in skeletal and cardiac muscle and at lower level in other tissues. Bag3 is involved in a panoply of cellular processes such as development, apoptosis, autophagy, cytoskeleton organization, cell adhesion and motility [4]. The clinical presentation of BAG3-related MFM is usually characterized by limb and axial muscle weakness, peripheral neuropathy, cardiomyopathy and respiratory failure. In these patients the mutation P209L re-occur at a high frequency. In the typical presentation of MFM due to BAG3 mutation, childhood cases can be particularly severe with rapid progression of the clinical picture and death in early adolescence [5-7]. With the aim of contributing to better defining the natural history of BAG3-related MFM, we report here a Caucasian 16-year-old male patient with the p.Pro209Leu (c.626C > T) in exon 3 mutation and cardiomyopathy as first clinical sign associated with peripheral neuropathy and MFM due to BAG3 mutation.

Case report

The 16-year-old Caucasian male had a negative family history for neurological disease and normal physiological history. Developmental milestones were normal. At 4 years a heart murmur was discovered and cardiological examinations led to a diagnosis of hypertrophic obstructive cardiomyopathy (HOC). He started therapy with metoprolol. At 8 years, he was hospitalized for fatigability and gait abnormalities. Increased creatine kinase (583 U/L) was detected, and HOC was stable. A diagnosis of myositis was made. The symptomatology then improved, but he was referred to the Pediatric Neuromuscular Clinic for associated mildly clumsy gait. Genetic analysis for Friedreich’s ataxia was negative. Neurological and neuromuscular examination at the age of 10 showed mild girdle and distal lower limb weakness (deltoids, biceps and triceps brachialis 4/5, tibialis anterior e peroneal muscles 4/5), pes cavus, rigid spine and ankle contractures with toe walking, positive Gower’s sign and absence of deep tendon reflexes in upper and lower limbs. Romberg maneuver was positive. Creatine kinase was increased (843 U/L). Nerve conduction study showed a severe sensory-motor axonal polyneuropathy with upper limbs motor conduction median nerve 37.5 m/s and ulnar nerve 40 m/s and slowed F wave. In the lower limbs, the compound motor action potential and the sensory action potential were not evocable. Muscle biopsy revealed, on the hematoxylin and eosin staining, myopathic changes with marked fiber size variability, atrophic fibers occasionally angulated, abundant centrally placed nuclei, necrosis and mild increase in connective tissue (Fig. 1A). Type I fibers were predominant. Multiple small vacuoles were present in numerous fibers (asterisks, Fig. 1A) and eosinophilic areas were observed in the cytoplasm of many fibers (arrows, Fig. 1A), the same strongly reactive with the Gomori trichrome staining (arrows, Fig.1B). Immunofluorescence analyses revealed ectopic expression of different sarcomeric protein like such as alphaB-crystallin (Fig. 1C) and myotilin (Fig. 1D).
Figure 1.

Morphological analyses of patient skeletal muscle tissue. A) hematoxylin and eosin (H&E) histological staining: protein inclusions and vacuoles indicated by arrows and asterisks, respectively (magnification 20x); B) trichrome Gomori staining: protein inclusions indicated by arrows (magnification 20x); C,D) immunofluorescence analyses with anti-alpha B crystallin(1C) and anti-myotilin (1D) antibodies showed protein aggregates inside the fibers (magnification 10x); E-G) ultrastructural analyses with Transmission Electron Microscopy (TEM) showed abnormal myofibrillar structures and Z-disk streaming.

Ultrastructural analysis confirmed the presence of severe signs of myofibrillar disruption with accumulation of electron dense granulo-filamentous materials in the intermyofibrillar space (Fig. 1E, Z-disk streaming, Fig. 1F) and abnormal extension of electron dense Z-bands (Fig. 1G).

Genetic analysis

LMNA, Desmin, alfaB-crystallin, myotilin e LDB3 genes didn’t show mutations. We performed the analysis of an NGS panel that include 169 genes associated with neuromuscular conditions (MotorPlex) 8. Coverage was at least 50x for > 98% of target. We also included parents in the NGS study, and we discovered a single heterozygous mutation p.Pro209Leu (c.626C > T NM_004281.4 ) in exon 3 of BAG 3 gene. This variant is currently not listed in gnomAD, and it is predicted to be pathogenic according to the ACMG/AMP criteria confirming the diagnosis of BAG3-myopathy. It was a de novo mutation, absent in the parents. At 4 years the electrocardiogram showed left atrial enlargement and left ventricle hypertrophy, while the echocardiogram showed hypertrophic obstructive cardiomyopathy with a peak left ventricular outflow tract (LVOT) gradient of 50 mmHg; the interventricular septum thickness was 16 mm, the middle septum 17 mm, the posterior basal septum and the anterior basal septum18 mm. The systolic function was normal (left ventricle ejection fraction, EF: 50%), while in diastole the left ventricle had high filling pressure. Subsequently, during the follow-up period, the features of the cardiomyopathy changed, the LVOT obstruction disappeared, but the restrictive pattern worsened with increase in the filling pressure of the left ventricle. The cardiac catheterization showed slight postcapillary pulmonary hypertension with mild increase in vascular pulmonary resistance. At 11 years hypercapnic restrictive respiratory failure (paCO2 84 mmHg) occurred. Hospitalization in the Cardiological Intensive Care Unit and pulmonary assessment were necessary. Since then he needed non-invasive ventilation (NIV), first only at night, then also all day. Idebenone 600 mg/day was added to the therapy. At 16 years, standing is possible with support and he is able to walk with support for a few minutes. Kyphoscoliosis is very severe. He becomes tired very easily. The weight is 33 kilos. The EF of the left ventricle is 55%. Dysphagia is not present and speech is fluent. He presented an episode of acute congestive heart failure which was treated till the remission of the acute phase. His cognitive performances are very good.

Discussion

BAG3-related MFM is a rare condition, in most cases due to a de novo mutation, and causes severe symptoms with rapidly progressive muscle, nerve, respiratory and heart involvement. The heterozygous mutation p.Pro209Leu (c.626C > T) has previously been identified in several patients and seems to be particularly associated with a severe neuromuscular phenotype. Some variability in the onset and severity of the different symptoms seems to be, even if almost all pediatric cases reported in the literature have a negative prognosis, with quickly progressive worsening of cardiac and respiratory features until exitus, usually occurring within the second to third decade of life (Tab. I). Muscle pathology shows disrupted Z-disks, disorganization of sarcomeric structures, cytosolic aggregated proteins and ectopic accumulation of various myofibrillar proteins and organelles, sign of protein quality control (PQC) and proteolytic systems dysfunction [9]. Studies on a zebrafish model of BAG3 P209L [10] demonstrated a relation between mutated BAG3, protein aggregates and autophagy (a degradation mechanism for damaged proteins in older cells) impairment. However, these studies revealed that mutated Bag3 maintained its function and did not cause protein aggregation but only myofibrillar disruption. Moreover, they demonstrated that aggregate formation was due to the gradual reduction of BAG3 availability caused by itself trapping inside the aggregate. Dysfunctional autophagy was reported in dilated cardiomyopathy due to BAG3 p.Pro209Leu mutation in patient cardiac tissue which demonstrated an increase in autophagy and mitophagy markers [11].
Table I.

Cases reports in the literature.

ReferenceAge at onset (years)Features at onsetCardiomyopathyContracturesWeaknessPeripheral neuropathyRespiratory failureOutcomeBAG3 mutation
Odgerel et al., 20105Not reportedRestrictive-hypertrophicNot reportedYesAxonal neuropathyYesSudden death at 9 yearsP209L
Odgerel et al., 201012Not reportedRestrictive-hypertrophic heart transplantationNot reportedYesAxonal neuropathyYesNot ambulantPro209L
Odgerel et al., 201012pes cavus, weakness, cardiopathyRestrictive hypertrophicScoliosis and rigide spineDistal weakness and neck weaknessAxonal neuropathyYesDeath at 20 yearsP209L de novo
Odgerel et al., 20105Gait disturbanceRestrictive-hypertrophic heart transplantationNot reportedProximal weaknessAxonal neuropathyYesDeath at 15 yearsP209L de novo
Lee HC et al., 20126Gait disturbanceRestrictive hypertrophicMultiple contractures and rigide spineMild proximal weaknessAxonal neuropathyNot reportedAmbulant at 12 yearsP209L de novo
D’avila et al., 201611ContracturesHypertrophic and arhytmiaRigide spineProximal weaknessAxonal neuropathyYesNot ambulantP209L de novo
Selcen et al., 2009ToddlerToe walkerrestrictive heart transplantToe walkerSevere weaknessNot reportedYesnot reportedNot reported
Selcen et al., 200913Scoliosis rigide spine, fatigabilityhypertrophicScoliosis and rigide spineDistal and proximal weaknessAxonal demyelinating neuropathyYesnot reportedNot reported
Selcen et al., 2009ToddlerToe walkerRestrictiveScoliosis, rigide spine and toe walkerProgressive proximal weaknessNot reportedYesDeath at 13 yearsNot reported
Jaffer et al., 2012ToddlerToe walkerRestrictive-hearth transplantationMultiple contractures and rigide spineDistal and proximal weaknessAxonal neuropathyNot reportedNot ambulantP209L de novo
Jaffer et al., 2012ToddlerToe walkerRestrictiveMultiple contractures, scoliosis and rigide spineDistal and proximal weaknessAxonal neuropathyYesAmbulant at 13,5 yearsP209L de novo
Kostera Pruszczyk et al., 201512Toe walker and foot deformityRestrictive (subclinical) long QTRigide spine and multiple contracturesSubclinical weaknessAxonal demyelinating neuropathyNoAmbulant at 15 yearsNot reported
Konersman et al., 2015Not reportedCardiopathyrestrictive heart transplantRigide spineSevere weaknessSensory-motor neuropathyNot reportedNot ambulantP209L de novo
Seung Ju Kim et al., 201811Gait disturbance and rigid spineNoRigide spine and multiple contracturesnot reportedAxonal neuropathyyesNot reportedP209L de novo
Noury et al., 2018Not reportedNot reportedNoRigide spinenot reportedAxonal sensory -motor neuropathyNot reportedNot reportedNot reported
Current report4CardiopathyRestrictive-hypertrophicMultiple contractures and rigide spineProximal weakness and mild distal weaknessAxonal neuropathyYesAmbulant with supportP209L de novo
The clinical phenotype in our patient is characterized by early onset HOC, early multiple contractures with rigid spine, non-severe proximal and distal weakness, severe axonal motor sensory neuropathy and severe progressive respiratory failure. Symptoms started with HOC at the age of 4 and the evolution of the clinical picture was initially relatively slow. A similar early onset of HOC is reported in other cases, while sometimes heart symptoms appear later, in the adolescence. In BAG3 mutated cases cardiomyopathy can be isolated and progressive and often leads to heart transplantation before the onset of other symptoms. Currently, at the age of 16, in our patient the cardiological picture shows stability of concentric ventricular hypertrophy with preserved global function. The role played by the treatment with idebenone is probably negligible and the involvement of oxidative metabolism in BAG3-related MFM has not been demonstrated to date. However, a favorable effect on a possible secondary mitochondrial dysfunction cannot be excluded. A possible explanation of the pathologic mechanisms underlying dilated cardiomyopathy in BAG3-related MFM is reported in a recent study of Mc Dermott-Roe et al. [12]. Their data imply a pathologic mechanism in which BAG3-RH improperly engages HSC/HSP70: this impairs the formation of multimeric chaperone complexes required for essential protein quality control including, but likely not limited to, myofibrillar maintenance. The observation that fiber disorganization was only apparent when cells were forced to use autophagy suggests that BAG3 variant expressivity is influenced by age-related dynamics in protein quality control subsystem usage. This provides a potential explanation for the delayed onset of BAG3-associated dilated cardiomyopathy and heart failure, often characterized by an aggressive clinical course. Moreover, male sex, low left ventricular EF (< 50%) and increased left ventricular end-diastolic diameter at first evaluation seem associated with an adverse prognosis during follow-up [13]. At 11 years our patient had acute respiratory failure and he began NIV. The worsening of the respiratory function is reported as an early symptom also in the other cases, and BAG3 myopathy has been demonstrated to meet pathologic criteria for hereditary myopathy with early respiratory failure (HMERF), an adult-onset autosomal-dominant myopathy, which typically presents with respiratory muscle weakness in patients who are still ambulant [13]. On the other hand, in BAG3-related MFM multiple contractures and rigid spine may also be present early on and usually worsen with time. These findings may justify the restrictive respiratory failure that is reported in some cases as early onset symptom. Limb muscle weakness was symmetric and mild in our patient, more evident proximally, with mild deficit in distal districts, and unlike other reported cases, ambulation was still preserved with support at the follow-up, while scoliosis and respiratory involvement were severe. In conclusion, it is important to hypothesize a neuromuscular disorder caused by BAG3 mutations in the presence of early onset HOC (first decade of life) and/or peripheral neuropathy and MFM for a correct diagnosis and to monitor cardiac and respiratory functions, which have usually a bad prognosis. Our case provides further evidence of progressive multisystem clinical involvement of BAG3-related MFM. Natural history studies of BAG3-related MFM are necessary especially in case pharmacological treatments are to be identified, for example compounds resulted able to removing protein aggregates such as metformin [14].

Ethical consideration

We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Acknowledgement

None.

Funding

None.

Conflict of interest

None of the authors has any conflict of interest to disclose.

Author contributions

GS wrote the manuscript. AP and MG visited the patient and collected clinical informations. AP coordinated the contributes of each co-Author to the paper. MLV performed muscle biopsy hystological and immunofluorescence analyses. MC performed muscle ultrastructural analyses. AT and VN performed NGS genetic analyses. LR performed cardiolgical assessment. Morphological analyses of patient skeletal muscle tissue. A) hematoxylin and eosin (H&E) histological staining: protein inclusions and vacuoles indicated by arrows and asterisks, respectively (magnification 20x); B) trichrome Gomori staining: protein inclusions indicated by arrows (magnification 20x); C,D) immunofluorescence analyses with anti-alpha B crystallin(1C) and anti-myotilin (1D) antibodies showed protein aggregates inside the fibers (magnification 10x); E-G) ultrastructural analyses with Transmission Electron Microscopy (TEM) showed abnormal myofibrillar structures and Z-disk streaming. Cases reports in the literature.
  14 in total

1.  BAG3 myofibrillar myopathy presenting with cardiomyopathy.

Authors:  Chamindra G Konersman; Brett J Bordini; Gunter Scharer; Michael W Lawlor; Steven Zangwill; James F Southern; Louella Amos; Gabrielle C Geddes; Robert Kliegman; Michael P Collins
Journal:  Neuromuscul Disord       Date:  2015-02-04       Impact factor: 4.296

2.  Dilated Cardiomyopathy Due to BLC2-Associated Athanogene 3 (BAG3) Mutations.

Authors:  Fernando Domínguez; Sofía Cuenca; Zofia Bilińska; Rocío Toro; Eric Villard; Roberto Barriales-Villa; Juan Pablo Ochoa; Folkert Asselbergs; Arjan Sammani; Maria Franaszczyk; Mohammed Akhtar; Maria José Coronado-Albi; Diego Rangel-Sousa; Jose F Rodriguez-Palomares; Juan Jiménez-Jáimez; José Manuel Garcia-Pinilla; Tomás Ripoll-Vera; Maria Victoria Mogollón-Jiménez; Ana Fontalba-Romero; Dolores Garcia-Medina; Julian Palomino-Doza; David de Gonzalo-Calvo; Marcos Cicerchia; Joel Salazar-Mendiguchia; Clara Salas; Sabine Pankuweit; Thomas Morris Hey; Jens Mogensen; Paul J Barton; Philippe Charron; Perry Elliott; Pablo Garcia-Pavia
Journal:  J Am Coll Cardiol       Date:  2018-11-13       Impact factor: 24.094

3.  Zebrafish models of BAG3 myofibrillar myopathy suggest a toxic gain of function leading to BAG3 insufficiency.

Authors:  Avnika A Ruparelia; Viola Oorschot; Raquel Vaz; Georg Ramm; Robert J Bryson-Richardson
Journal:  Acta Neuropathol       Date:  2014-10-02       Impact factor: 17.088

4.  Investigation of a dilated cardiomyopathy-associated variant in BAG3 using genome-edited iPSC-derived cardiomyocytes.

Authors:  Chris McDermott-Roe; Wenjian Lv; Tania Maximova; Shogo Wada; John Bukowy; Maribel Marquez; Shuping Lai; Amarda Shehu; Ivor Benjamin; Aron Geurts; Kiran Musunuru
Journal:  JCI Insight       Date:  2019-11-14

5.  Mutation in BAG3 causes severe dominant childhood muscular dystrophy.

Authors:  Duygu Selcen; Francesco Muntoni; Barbara K Burton; Elena Pegoraro; Caroline Sewry; Anna V Bite; Andrew G Engel
Journal:  Ann Neurol       Date:  2009-01       Impact factor: 10.422

6.  Metformin rescues muscle function in BAG3 myofibrillar myopathy models.

Authors:  Avnika A Ruparelia; Emily A McKaige; Caitlin Williams; Keith E Schulze; Margit Fuchs; Viola Oorschot; Emmanuelle Lacene; Mirella Meregalli; Clara Lee; Rita J Serrano; Emily C Baxter; Keyne Monro; Yvan Torrente; Georg Ramm; Tanya Stojkovic; Josée N Lavoie; Robert J Bryson-Richardson
Journal:  Autophagy       Date:  2020-10-19       Impact factor: 16.016

Review 7.  Respiratory management of patients with neuromuscular disease: current perspectives.

Authors:  Gerald Pfeffer; Marcus Povitz
Journal:  Degener Neurol Neuromuscul Dis       Date:  2016-11-18

8.  Inheritance patterns and phenotypic features of myofibrillar myopathy associated with a BAG3 mutation.

Authors:  Zagaa Odgerel; Anna Sarkozy; Hee-Suk Lee; Caoimhe McKenna; Julia Rankin; Volker Straub; Hanns Lochmüller; Francalanci Paola; Adele D'Amico; Enrico Bertini; Kate Bushby; Lev G Goldfarb
Journal:  Neuromuscul Disord       Date:  2010-06-03       Impact factor: 4.296

9.  MotorPlex provides accurate variant detection across large muscle genes both in single myopathic patients and in pools of DNA samples.

Authors:  Marco Savarese; Giuseppina Di Fruscio; Margherita Mutarelli; Annalaura Torella; Francesca Magri; Filippo Maria Santorelli; Giacomo Pietro Comi; Claudio Bruno; Vincenzo Nigro
Journal:  Acta Neuropathol Commun       Date:  2014-09-11       Impact factor: 7.801

10.  Exome sequencing identifies variants in two genes encoding the LIM-proteins NRAP and FHL1 in an Italian patient with BAG3 myofibrillar myopathy.

Authors:  Francesca D'Avila; Mirella Meregalli; Sara Lupoli; Matteo Barcella; Alessandro Orro; Francesca De Santis; Clementina Sitzia; Andrea Farini; Pasqualina D'Ursi; Silvia Erratico; Riccardo Cristofani; Luciano Milanesi; Daniele Braga; Daniele Cusi; Angelo Poletti; Cristina Barlassina; Yvan Torrente
Journal:  J Muscle Res Cell Motil       Date:  2016-07-21       Impact factor: 2.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.